However, grade-three or above adverse effects have been reported in patients treated with regorafenib, including heart failure, hypertension, thrombocytopenia, hyperbilirubinemia, increased aspartate aminotransferase and alanine aminotransferase, and gastrointestinal toxicities [7,44,45,46]. This evidence concerns the gene GPT and hypertensive disorder.